NCT03284593Active, not recruiting
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition at Toulouse and Bordeaux University Hospital
Source: ClinicalTrials.gov · Last updated 30 Jul 2020
Brief summary (registry, in English)
The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 199 (actual)
- First submitted
- 13 Sept 2017
- Start date
- 1 Dec 2014
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT03284593
What you commit to
- Study type: Observational
- Participants enrolled: 199
- From 1 Dec 2014 to the primary completion date, 31 Dec 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- patients with acute myeloid leukemia
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Bordeaux Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| University Hospital, Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.